September 17, 2020
Amwell made its debut on the New York Stock Exchange today after announcing late Wednesday night the pricing for its upsized initial public offering of about 41.2 million shares of Class A common stock at $18 per share.
The updated pricing equates in total gross proceeds of approximately $742 million, before deducting underwriting discounts and commissions and offering expenses payable by Amwell...
August 25, 2020
Telehealth giant Amwell has officially filed to go public, fueled with a $100 million funding boost from Google’s cloud division.
The funding also comes with a partnership agreement, which designates Amwell as Google Cloud's preferred telehealth provider, and vice versa for Google’s cloud platform.
The pair will also collaborate on technology, specifically bringing together AmWell’s telehealth...
August 4, 2020
GoodRx, an online pharmacy platform for low-cost prescriptions and price comparisons, has submitted the SEC forms necessary for an IPO, Reuters reports.
The timing of the startup's listing is still in the air, however, with 2020 and early 2021 both on the table depending on developments in the market, according to the anonymous source. GoodRx is still in the process of hiring advisors for the...
August 3, 2020
Israeli "digital X-ray" startup Nanox filed a Form F-1 with the SEC on Friday that outlines plans to raise $125 million in an IPO.
The company has applied to list its shares on the Nasdaq exchange as "NNOX," and according to a representative has entered its quiet period prior to the IPO.
Nanox, which has raised $110 million from investors since November 2019, is building a two-part offering...
July 31, 2020
SOC Telemed, formerly Specialists on Call, will join the Nasdaq stock exchange by merging with Healthcare Merger Corporation, a special purpose acquisition company. Sometimes referred to as a "blank check" acquisition, merging with a special purpose acquisition company is an alternate way for a company to go public.
The combined company will operate under the name SOC Telemed and will be listed...
July 23, 2020
Consumer wellness and telehealth company Hims could be the next to throw its hat into the public markets.
According to a report from Reuters, the startup is weighing a potential sale to an unnamed special purpose acquisition company (SPAC) – a "blank-check company" that uses the proceeds of an IPO to acquire or merge another business.
The deal would value Hims at over $1 billion, Reuters' sources...
July 14, 2020
Decentralized digital therapeutic trial. Pear Therapeutics has enrolled the first participant in the DREAM study, an open-label trial of its Somryst prescription digital therapeutic for chronic insomnia.
Conducted as a decentralized trial, the effort will recruit U.S. adults aged 22 to 75 years who have an Insomnia Severity Index score of 8 or higher, as well as at least three months of insomnia...
June 8, 2020
Telemedicine giant AmWell is looking to go public, following a surge in use amid the coronavirus, CNBC first reported. The company declined to comment on news of the IPO when MobiHealthNews reached out.
CNBC is reporting that the Boston-based company hired Goldman Sachs and Morgan Stanley to broker the deal, which is expected to take place in September.
This news comes only weeks after the...
March 2, 2020
Health-benefits navigation platform Accolade announced on Friday the filing of its S-1 with the US Securities and Exchange Commission, making it the next digital-health company in line to join the public markets.
Accolade has set a $100 million maximum aggregate offering price to calculate its registration fee, but has not yet locked down the price and volume of its share offering.
January 31, 2020
Tech-enabled primary care business 1Life Healthcare — better known by its brand name, One Medical — hit the public market Friday after announcing the sale of 17.5 million shares at $14 each. This pricing alongside the roughly 122 million outstanding shares disclosed in the company’s S-1 would put One Medical’s valuation at just over $1.7 billion.
And although it’s only been on the market for a...